Norwegian version of this page

Diseases of esophagus and stomach

The group consists expertise within surgery, oncology, pathology and translator research working for improvement of diagnostics and treatment.

About the group

  • Oncologic and surgical treatment of patients with esophageal and gastric cancer (morbidity, survival, health related quality of life) 

  • Treatment of patients with benign esophageal diseases (perforations, achalasia, diverticula)

  • Treatment of hiatal hernias and incisional hernias

  • Translatory studies aiming at identifying biomarkers for early detection of cancer

Projects and Research

  • Continual monitoring of complications and survival (quality assurance) following resection for esophageal- and gastric cancer

  • Continual biobanking of blood samples and tumor tissue from esophageal cancer and gastric cancer since 2013 for research purposes.  Analyses of biobank material have been ongoing since 2019.

  • A PhD study on local treatment of dysplasia and early cancer as well as hybrid and total minimally invasive resection for stage I-III esophageal cancer is ongoing. 

  • NeoRes II, Scandinavian multicenter randomized study  evaluating effect of awaiting surgery after chemoradiotherapy (CROSS regimen) for 4-6 versus 10-12 weeks is terminated and some results have been published. 

  • The INNOVATION study. European randomised multicenter study, in which patients with HER-2 positive gastric cancer were randomized in three arms for i) chemotherapy, ii) chemotherapy with trastuzumab or iii) chemotherapy with trastuzumab+pertuzumab. End point is overall survival.  EORTC study. Inclusion is still ongoing. 

  • INTENSE study.  Effect of perioperative use of chemotherapy with 4 cycles of FOLFIXFLIRI x 2 in patients with resectable gastric and gastroesophageal junction adenocarcinoma.  Ongoing inclusion.

  • The INEC study is a phase I/II studie run from Oslo University Hospital, where a combination of check-point PD-1 inhibitor (Nivolumab) and different oncologic treatments (palliative radiation/definitive CRT/neoadjuvant CRT) against the esophageal tumor are compared.

  • In the VESTIGE study inclusion in Norway started in January 2020, of patients with high risk for recurrence after surgery with N+ or R1 resection. These patients will receive adjuvant chemotherapy or ipilimumab for 1 year + nivolumab for 1 year.

  • •NEEDS study started in 2021. Neoadjuvant chemoradiotherapy for esophageal  squamous cell carcinoma and esophagectomy versus definitive chemoradiotherapy with salvage surgery as needed. Planned to start primo 2021.

  • The group is involved in research on neuroendocrine carcinomas (NEC).

  • Participation in recruitement of patients via the The upper GI International Robotic Association (UGIRA) responsible for the International Registry for Robot-Assisted Minimally Invasive Gastretomy (RAMIG), localised in Utrecht, The Netherlands

  • Participation in the kinetic study- a Register based Randomised Controlled Trial-Ng-tube post-EsophagecTomy Complications. This Scandinavian multicenter study, run from Uppsala, Sweden, compares complications (pneumonia) post esophagectomy related to whether or not a nasogastric tube is used.

Cooperation

Internal

  • Truls Hauge and colleagues at Gastromedical Dep.,OUS,Ullevål

  • Geir Olav Hjortland and colleagues at the Oncological department,OUS,Ullevål

  • Guro Elisabeth Lind and colleagues at Dep. of Molecular Oncology, Institute of Cancer Reseach, OUS,DNR  

  • Colleagues at the university clinics in Tromsø, Trondheim and Bergen

International

  • Magnus Nilsson and colleagues at the Gastrosurgical dep., Karolinska University Hospital, Sweden

  • Jacob Hedberg, Dep. Surgical Sciences, Uppsala, Sweden

  • C. de Jongh, University Medical Center, Utrecht, Netherlands

Selected Publications

  • Nilsson K, Klevebro F, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Hjortland GO, Bartella I, Schröder W, Bruns C, Nilsson M. Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Ann Surg. 2020 Nov;272(5):684-689. doi: 10.1097/SLA.0000000000004340. PMID: 32833767.

  • Mala T, Førland DT, Vetti HH, Skagemo CU, Johannessen HO, Johnson E. Gastrisk adenokarsinom og proksimal ventrikkelpolypose – en sjelden form for arvelig magesekkreft [Gastric adenocarcinoma and proximal polyposis of the stomach – a rare form of hereditary gastric cancer]. Tidsskr Nor Laegeforen. 2020 May 4;140(7). Norwegian. doi: 10.4045/tidsskr.19.0480. PMID: 32378851.

  • Gharagozlian S, Mala T, Brekke HK, Kolbjørnsen LC, Ullerud ÅA, Johnson E. Nutritional status, sarcopenia, gastrointestinal symptoms and quality of life after gastrectomy for cancer - A cross-sectional pilot study.Clin Nutr ESPEN. 2020 Jun;37:195-201. doi:10.1016/j.clnesp.2020.03.001. Epub 2020 Mar 14. PMID:32359743             

  • Hauge T, Amdal CD, Falk RS, Johannessen HO, Johnson E. Long-term outcome in patients operated with hybrid esophagectomy for esophageal cancer - a cohort study. Acta Oncol. 2020 Apr 23:1-7. doi: 10.1080/0284186X.2020.1750694. [Epub ahead of print] PMID:32324079

  • Hauge T, Franco-Lie I, Løberg EM, Hauge T, Johnson E. Outcome after endoscopic treatment for dysplasia and superficial esophageal cancer – a cohort study. Scand J Gastroenterol 2020; DOI 10.1080/00365521.2020.180813

  • Ali AS, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS One. 2020 Dec 14;15(12):e0243900. doi: 10.1371/journal.pone.0243900. PMID: 33315908; PMCID: PMC7735636.

  • Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS, Vestermark LW, Ali AS, Zlobec I, Myklebust TÅ, Hjortland GO, Langer SW, Gronbæk  H, Knigge U, Tiensuu Janson E, Sorbye H. A consensus developed morphological re-evaluation of 196 high-grade gastroenteropancreatic neuroendocrine neoplasms and its clinical correlations. Neuroendocrinology. 2020 Oct 1. doi: 10.1159/000511905. Epub ahead of print. PMID: 33002892

  • Claassen YHM, Bastiannet E, Hartgrink HH, Dikken JL, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Shutter H, Lindblad M, Hedberg J, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Koessler T, Chevallay M, Allum WH, van de Velde CJH. International comparison of treatment strategy and survival in metastatic gastric cancer. BJS Open. 2019;3:56-61.    

  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome after iatrogenic esophageal perforation. Scand J Gastroenterol. 2019 Feb;54(2):140-144.

  • Mala T, Johannessen HO, Førland D, Jacobsen TH, Johnson E. Laparoscopic resection for gastric cancer at Oslo University Hospital, Ullevål 2015-18. Tidsskr Nor Laegeforen. 2018 Nov 5; 138 (18). Doi:10.4045/tidsskr. 18.0404.

  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome after stenting and débridement for spontaneous esophageal rupture. Scand J Gastroenterol 2018;53(4):398-402.

  • Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis. Eur J Surg Oncol. 2018;44(12):1982-1989. 

  • Hauge T, Kleven OC, Johnson E, Hofstad B, Johannessen HO. Outcome food bolus induced esophageal perforation.  Scand J Gastroenterol 2018;53(8):905-909.

  • Amdal CD, Jacobsen AB, Falk RS, Johnson E, OS SS, Warloe T, Bjordal K. Improved treatment decisions in patients with esophageal cancer. Acta Oncol 2017;56(10):1286-1294.

  • Galleberg RB, Knigge U, Tiensu JE, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H,  Österlund P, Hjortland GO, Assmus J, Tang L, Perren A. Sorbye H. Results after surgical treatment in  patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. Eur J Surg Oncol  2017; 43 (9):1682-89. 

  • Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer S, Welin S, Vestermark LW, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET. “Expression of p53 protein in high-grade gastroenteropancreatic  neuroendocrine carcinoma (WHO G3)”. PLoS  One 12(11):e0187667, Nov7 2017. 

  • Li Y, Li X, Kan Q, Zhang M, Li X, Xu R, Wang J, Goscinski MA, Wen JG, Nesland JM, Suo Z. Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. Oncotarget 2017;8(1):1058-73.

 

Published Aug. 10, 2018 10:33 AM - Last modified June 28, 2021 4:08 PM

Contact

Group Leader

Participants

  • Else Marit Løberg
  • Al-Haidari Ghazwan
  • Brit Dybdahl
  • Caroloine Ursin skagemo
  • Dag T. Førland
  • Geir Olav Hjortland
  • Hans-Olaf Johannessen
  • Jorunn Skattum
  • Tobias Hauge
  • Tom Glomsaker
  • Torgeir Thorson Søvik
Detailed list of participants